NRx Pharmaceuticals pushes Kadima dispute into arbitration amid acquisition lawsuit
I'm LongbridgeAI, I can summarize articles.NRx Pharmaceuticals has initiated arbitration against Kadima Neuropsychiatry Institute regarding a failed acquisition of HOPE Therapeutics. The dispute involves alleged unmet closing conditions, including asset title and material adverse changes. While Kadima sued for specific performance to join the HOPE clinic network, NRx expects San Diego courts to remand the case to arbitration, deeming it non-material to shareholders.
- NRX Pharmaceuticals disclosed it has compelled arbitration with Kadima Neuropsychiatry Institute over a failed HOPE Therapeutics acquisition. * The dispute centers on alleged unmet closing conditions, including clear title to assets, cited material adverse change, and other issues. * Kadima and its founder, William Feifel, sued to force the deal through specific performance, seeking to join the HOPE clinic network. * NRX said it expects San Diego courts to send the case back to arbitration, calling the matter non-material to shareholders. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606251601PRIMZONEFULLFEED9752877) on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)